分化型甲状腺癌分子生物学的研究进展  

Recent developments of molecular biology in differentiated thyroid cancer

作　　者：郝智[1] 崔建英[2] 

机构地区：[1]保定市肿瘤医院头颈外科,保定071000 [2]保定市肿瘤医院神经内科,保定071000

出　　处：《中国当代医药》2013年第26期19-20,22,共3页China Modern Medicine

摘　　要：分化型甲状腺癌是最常见的内分泌系统肿瘤,近年来,分子生物学技术在甲状腺癌诊断、治疗方面取得了较大的进展,其中研究最多的就是BRAF、RET/PTC及P21-RAS等基因,本文就以上分子标志物的作用机制进行综述。Differentiated thyroid cancer is the most common endocrine system cancer in recent years, molecular biolo- gy technology has made great progress in the diagnosis, treatment of thyroid carcinoma, the most are the BRAF, RET/ PTC and P21-RAS genes, mechanism of these molecular markers are reviewed in this article.

关 键 词：分化型甲状腺癌 分子生物学 进展 

分 类 号：R736.1[医药卫生—肿瘤]